Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Forat Lutfi, MD, Ankit Kansagra, MD, Moaath Mustafa Ali, MD, Ali Bukhari, MD, Jonathan Siglin, BS, Jingsheng Yan, PhD, Santanu Samanta, MD, Noa G. Holtzman, MD, David Gottlieb, MD, Dong Won Kim, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Jean A. Yared, MD, Nancy M. Hardy, MD, Jason Molitoris, MD, Pranshu Mohindra, MD, Aaron P. Rapoport, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141231

Published: 2020

Journal Articles

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello, MD, Adam D. Cohen, MD, Krina K. Patel, MD, Syed S Ali, MD, Jesus G. Berdeja, MD, Nina Shah, MD, Siddhartha Ganguly, MD, Mehmet Hakan Kocoglu, MD, Mehrdad Abedi, MD, Eric M. Ostertag, MD PhD, Chris E Martin, PhD, Majid Ghoddussi, PhD, Devon J Shedlock, PhD, Joanne McCaigue, M.S., Hamid Namini, PhD, Sreeni Yalamanchili, Matthew A. Spear, MD, Tara K. Gregory, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142695

Published: 2020

Journal Articles

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD, Forat Lutfi, MD, Facundo Zafforoni, BS, Moaath Mustafa Ali, MD MPH, Ali Bukhari, MD, David Gottlieb, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Nancy M. Hardy, MD, Jean A. Yared, MD, Aaron P. Rapoport, MD, Jennie Y. Law, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141992

Published: 2020

Journal Articles

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Noa G. Holtzman, MD, Soren M. Bentzen, PhD DMSc, Vivek Kesari, MD, Ali Bukhari, MD, Firas El Chaer, MD, Elizabeth Hutnick, RN, Kathleen Ruehle, RN, Natalie Gahres, RN, Neil Porter, MD, Carl Shanholtz, MD, Mehmet Hakan Kocoglu, MD, Ashraf Z. Badros, Babak Saboury, MD MPH, Jean A. Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, Saurabh Dahiya, MD

Blood (2019) 134 (Supplement_1): 3239.

https://doi.org/10.1182/blood-2019-125400

Published: 2019

Journal Articles

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Ali Bukhari, MD, Vivek Kesari, MD, Reza Sirous, MD, Noa G. Holtzman, MD, Seung Tae Lee, MD PhD, Natalie Gahres, RN, Elizabeth Hutnick, RN, Kathleen Ruehle, RN, Mehmet Hakan Kocoglu, MD, Ashraf Z. Badros, Jean A. Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, Babak Saboury, MD MPH, Saurabh Dahiya, MD

Blood (2019) 134 (Supplement_1): 4454.

https://doi.org/10.1182/blood-2019-125794

Published: 2019

Journal Articles

POEMS Syndrome: A Review of Our Patient Population

Simran Arora Elder, MD BA, Mehmet Hakan Kocoglu, MD

Blood (2019) 134 (Supplement_1): 5516.

https://doi.org/10.1182/blood-2019-123414

Published: 2019

Journal Articles

Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma

Mehmet Hakan Kocoglu, MD, Ameet Patel, MD, Aaron P. Rapoport, MD, Ning Ma, CRNP, Jennifer Ding, MD, Simran Elder, MD BA, Aneesha Hossain, MD, Ashraf Z. Badros, MD

Blood (2018) 132 (Supplement 1): 5750.

https://doi.org/10.1182/blood-2018-99-117915

Published: 2018

NARROW

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

POEMS Syndrome: A Review of Our Patient Population

Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

POEMS Syndrome: A Review of Our Patient Population

Impact of Body Mass Index (BMI) on Survival Endpoints in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only